A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- Ratio of Generics Rises 0.3 Points to 23.8%: Survey
August 3, 2012
- PMDA Determines Role of Science Board to Enhance Review System
August 2, 2012
- Council Generally Approves Revised Basic Policy for 2nd Med. Expenditure Optimization Plan; Regional Targets for Use of Generics to Be Included
August 2, 2012
- MHLW Investigative Commission Compiles Report to Improve Distribution of Novel Influenza Vaccines
August 1, 2012
- Council Approves Economic Revitalization Strategy with Priority on 3 Sectors Including Life Science
August 1, 2012
- MHLW to Issue Development Requests for 8 Drugs/Indications Determined to Have Unmet Medical Needs by Council on Unapproved Drugs
August 1, 2012
- MHLW Withdraws Development Request for Decitabine in Response to Approval for New Drug with Same Indication
August 1, 2012
- MHLW to Use Senshin-iryo System to Develop Anticancer Drugs from FY2013
July 30, 2012
- MHLW Approves Class 1 OTC Drugs for Allergic Rhinitis
July 30, 2012
- MHLW Reports Revisions of Package Insert for Telavic
July 27, 2012
- PAFSC’s 2nd Committee Recommends Approval of 2 DPT-IPV Vaccines; Introduction Expected in November
July 26, 2012
- PAFSC’s 2nd Committee Recommends Orphan Drug Designation for 3 Products Including Thyroid Cancer Treatment
July 26, 2012
- MHLW Asks Sanofi Pasteur to Consider Reducing Price of IPV
July 25, 2012
- MHLW Approves Revision to Kitasato Daiichi Sankyo Vaccine’s Management Resource Reuse Plan
July 25, 2012
- PAFSC’s First Committee to Review 4 Products Including Lotriga from Takeda on August 3
July 24, 2012
- PAFSC’s Second Committee Recommends Approval for Symbicort for COPD
July 24, 2012
- NIBIO to Play Important Role in Collaboration between Industry, Government, Academia: Director General Yamanishi
July 24, 2012
- Expert Panel Recommends Priority Measures Including Pediatric Drug Development for FY2013 Budget
July 23, 2012
- Mix of Differential Pricing and Generic Drug Use Promotion Policies Can Help Reduce Drug Expenditure: Prof. Sakamaki
July 23, 2012
- MHLW Study Group Launches Info Website on Epilepsy Treatment Facilities
July 23, 2012
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…